• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Clinical Development Year in Review (2013)
 

Clinical Development Year in Review (2013)

on

  • 166 views

In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic ...

In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic options for sponsors seeking to outsource large studies. There will be more competition for large studies and the large CROs depend on large studies for their growth.

Statistics

Views

Total Views
166
Views on SlideShare
166
Embed Views
0

Actions

Likes
0
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Clinical Development Year in Review (2013)  Clinical Development Year in Review (2013) Presentation Transcript

    • In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic options for sponsors seeking to outsource large studies. There will be more competition for large studies and the large CROs depend on large studies for their growth. CRO REVENUE & BACKLOG R&D RESTRUCTURING Quintiles, PAREXEL, Covance, ICON, and Charles River Revenue $24.03B Backlog $3.22B $3.26B Q1,2013 Merck Announces Global Initiative to CRO MERGERS & PARTNERSHIPS Q3,2013 STOCK PRICES FARE OK June 1st to December 1st 2013 IHE (Pharmaceutical Industry Index Fund) is up 35% for the first 11 months of 2013 vs. the Dow Jones Industrial Average which is up “only” 24% over the same period Post-restructuring, Pfizer R&D focused on its top blockbuster prospects $3.05B Q2,2013 2013 • IHE is up 18% • DJIA is up 8% • Quintiles is up 1% PAREXEL is down 8% • ICON is up 13% • Covance is up 17% Based on ISR’s market sizing model, we estimate that the top 5 CROs account for ~50% of the total market and the top 8 CROs account for ~66% of the market. But overall, sponsors are not overly satisfied with the outsourcing models currently employed. Fewer than 6% of respondents are “completely satisfied” with their outsourcing. Quintiles Merck Serono 100 283 283 122 269 308 281 278 259 260 242 238 338 298 264 154 96 100 114 1 2 4 6 3 Q4,2011 Q1,2012 Q2,2012 Q3,2012 Q4,2012 296 240 216 93 5 1 Q1,2013 Q2,2013 ISR Research www.contractpharma.com www.fiercebiotech.com online.wsj.com www.mercknewsroom.com ir.kkr.com KKR Quintiles PPD JLL RPS Novella Acurian BioClinica PRA 392 319 AQUISITIONS: PARTNERSHIPS: CLINICAL TRIAL SUBMISSIONS 326 287 283 Forest Labs to Cut 9% of Workforce Novartis plots sales cuts in U.K. amid Sharpen Commercial and R&D Focus R&D restructuring Eisai slashes U.K. R&D jobs in 'global' restructuring $23.64 B $23.31 B AZ Restructures, To Build New HQ 310 Phase Phase Phase Phase Phase 0 I II III IV CoreLab 1st 3 Quarters of 2012 $60.9B $57.8B 1st 3 Quarters of 2013 223 210 R&D SPENDING STAYS FLAT 90 6 Q3,2013 www.quintiles.com www.ppdi.com www.bioclinica.com www.google.com/finance www.clinicaltrials.gov Bloomberg BusinessWeek Quintiles, PAREXEL, Covance, ICON, and Charles River Quarterly Reports $17.4B $17.2B $1.6B $1.9B Pharma ISRreports.com Biotech | Generic info@ISRreports.com | @ISRreports